Breast Cancer
Veliparib ABT-888 Neoadj TNBC
USON 12152: A Randomized, Placebo-Controlled, Double-Blind, Phase III Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer

Niraparib vs PhyChoice HER2-gBRCA Breast
USON 13112: A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician’s Choice in Previously-Treated, Her2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Gynecologic Cancer
Trabectedin +/- PLD adv Ovarian 2/ 3 In
USON 12232: A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Leukemia & Lymphoma
Rev+Ritux, R/R FL, MZL, MCL
USON 13064: A Phase IIIB Randomized Study of Lenalidomide Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Idela + Ritux, ILn CLL, 17p Del
USON 13142: A Phase II, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

GS-9973 (Syk Inh) in R/R Heme Malig
USON 12154: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies

Brentuximab Vedotin in Older Pts with HL
USON 11282: A Phase II Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin lymphoma (HL) in Adults Age 60 and Above

Melanoma
LGX818 +/- MEK162 v Vem Melanoma
USON 13079: A Phase III Randomized, 3-Arm, Open Label, Multicenter Study of LGX818 plus MEK162 and LGX818 Monotherapy Compared with Vemurafenib in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma

Ovarian Cancer
Maint Niraparib PlatSensOvarian
USON 13008: A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

Gem/Carbo+LY2228820 2Ln plat sen OvCa
USON 10312: A Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer

Pancreatic Cancer
PEGPH20+Nab+Gem Stage IV Pancr
USON 12237: A Phase II, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Ph3 Jak Inhibitor w Cape for mPC
USON 13197: A Randomized, Double-Blind, Phase III Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or are Intolerant to First-Line Chemotherapy

For more information or to refer a patient, call 855-880-CURE.

Trial listing current as of 3/2015.
**Prostate Cancer**

DCVAC/PCa +SOC v Placebo in metCRP

USON 13024: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

**Renal Cancer**

Axitinib +/- Dalantercept Adv RCC

USON 14091: A Phase II Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma

---

**RADIATION CLINICAL TRIALS**

**Breast Cancer**

Post-Mastctomy/Lumpctmy XRT, Neoadj Chemo

USON 13091: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

**Head and Neck Cancer**

IMRT+/-Cetuximab H&N

USON 10025: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG0920)

**Glioblastoma**

Standard vs High Dose XRT + Temozolomide in Glioblastoma

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

**Prostate Cancer**

STAD w/ Pelvic LN or Prostate RT

USON 08079: A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534)

Radiotherapy +/- Androgen Dep in Prost

USON 09200: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815